Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer

This is a prospective multicenter, open-label, Phase I clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of propranolol hydrochloride in combination with adebrelimab and platinum-based chemotherapy in patients with small cell lung cancer (SCLC).The study includes two cohorts: patients with previously untreated extensive-stage SCLC and patients with resectable early-stage (T1-2N0M0) SCLC. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the response

Trial Details

NCT ID
NCT07886047
Phase
PHASE1
Sponsor
Second Xiangya Hospital of Central South University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Propranolol Hydrochloride
  • Adebrelimab
  • Chemotherapy
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087
  • Changsha, Hunan, China|28.19874,112.97087
  • Changsha, Hunan, China|28.19874,112.97087
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Written informed consent must be obtained prior to any study-related procedures
  • Age ≥18 years and ≤75 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
  • Life expectancy ≥12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →